



	MD (Pathology	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist		Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist	
IAME	: Mrs. RITU				
GE/ GENDER	: 30 YRS/FEMALE	PATI	ENT ID	: 1574291	
COLLECTED BY	:	REG. 1	NO./LAB NO.	: 012408080008	
REFERRED BY	:	REGIS	STRATION DATE	: 08/Aug/2024 07:44 AM	
BARCODE NO.	: 01514682	COLL	ECTION DATE	: 08/Aug/2024 08:40AM	
LIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 08/Aug/2024 09:58AM	
LIENT ADDRESS	: 6349/1, NICHOLSON ROAD	AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
	CLIN	IICAL CHEMISTRY/	BIOCHEMISTR	Y	
		LIPID PROFILE	: BASIC		
CHOLESTEROL TOTA	L: SERUM	138.29	mg/dL	OPTIMAL: < 200.0	
by CHOLESTEROL OX	IDASE PAP		0	BORDERLINE HIGH: 200.0 - 239.0	
				HIGH CHOLESTEROL: > OR = 240.0	
FRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		183.12 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0	
				HIGH: 200.0 - 499.0	
				VERY HIGH: > OR = 500.0	
IDL CHOLESTEROL (by SELECTIVE INHIBIT		37.51	mg/dL	LOW HDL: < 30.0	
by SELECTIVE INITIDIT				BORDERLINE HIGH HDL: 30.0 - 60.0	
				HIGH HDL: $> OR = 60.0$	
DL CHOLESTEROL: S		64.16	mg/dL	OPTIMAL: < 100.0	
by CALCULATED, SPE	CTROPHOTOMETRY			ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0	
				HIGH: 160.0 - 189.0	
				VERY HIGH: > OR = 190.0	
NON HDL CHOLESTE		100.78	mg/dL	OPTIMAL: < 130.0	
by CALCULATED, SPE	CIROPHOIOMEIRY			ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0	
				HIGH: 190.0 - 219.0	
				VERY HIGH: > OR = 220.0	
LDL CHOLESTEROL:		36.62	mg/dL	0.00 - 45.00	
by CALCULATED, SPE OTAL LIPIDS: SERUI		459.7	mg/dL	350.00 - 700.00	
	CTROPHOTOMETRY				
•		3.69	RATIO	LOW RISK: 3.30 - 4.40	
CHOLESTEROL/HDL	CTDADUATAMETRY			AVERAGE RISK: 4.50 - 7.0	
	CTROPHOTOMETRY			MODERATE RISK \cdot 7 10 $_{-}$ 11 0	
CHOLESTEROL/HDL	CTROPHOTOMETRY			MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab:6349/1, Nicholson Road, Ambala Cantt -133 001, HaryanaKOS Molecular Lab:IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana0171-2643898, +91 99910 43898care@koshealthcare.comwww.koshealthcare.comwww.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





		Chopra y & Microbiology) Consultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. RITU			
AGE/ GENDER	: 30 YRS/FEMALE		PATIENT ID	: 1574291
COLLECTED BY	:		REG. NO./LAB NO.	: 012408080008
REFERRED BY	:	1	REGISTRATION DATE	: 08/Aug/2024 07:44 AM
BARCODE NO.	: 01514682		COLLECTION DATE	: 08/Aug/2024 08:40AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 08/Aug/2024 09:58AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	D, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
by CALCULATED, SPECTROPHOTOMETRY				MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM4.88by CALCULATED, SPECTROPHOTOMETRY4.88		4.88	RATIO	3.00 - 5.00

INTERPRETATION:

1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along

with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

